ABSTRACT A monoclonal antibody, 9.2.27, with a high specificity for human melanoma cell surfaces has been utilized for biosynthetic studies in M21 human melanoma cells to define a unique antigenic complex consisting ofa 250kdilodalton N-linked glycoprotein and a high molecular weight proteoglycan component larger than 400 kilodaltons. The 250-kilodalton glycoprotein has endoglycosidase H-sensitive precursors and shows a lower apparent molecular weight after treatment with neuraminidase. The biosynthesis of the proteoglycan component is inhibited by exposure of M21 cells to the monovalent ionophore monensin; this component can be labeled biosynthetically with 35SO4, is sensitive to 3-elimination in dilute base, and is degraded by both chondroitinase AC and ABC lyases, suggesting that it is a chondroitin sulfate proteoglycan. These data demonstrate that the antigenic determinant recognized by monoclonal antibody 9.2.27 is located on a glycoprotein-proteoglycan complex which may have unique implications for the interaction of glycoconjugates at the. human melanoma tumor cell surface.
The development ofmonoclonal antibodies to tumor cell surface components has provided specific probes to establish the molecular nature of these antigens. Antigenic determinants with unique biochemical properties defined by monoclonal antibodies specific for colorectal carcinoma have recently been identified as glycolipids (1) . Several additional monoclonal antibody reagents have defined components that appear to be either cellsurface or secreted glycoproteins of human tumors (2) (3) (4) . The high specificity of these monoclonal .antibody probes and their ability to immunoprecipitate antigens selectively from complex soluble tumor extracts permits the biochemical analysis ofthese potentially tumor-associated gene.products.
This laboratory has recently developed a. monoclonal antibody, 9.2.27 , that is directed against an antigen highly associated with the surface of all melanoma cell lines and frozen sections of fresh surgical melanoma specimens thus far examined (4) .
In this study, we utilized the 9.2.27 monoclonal antibody in a combination of biosynthetic and enzymatic. digestion studies to define a unique cell surface antigen that consists of a glycoprotein-proteoglycan complex expressed on the surface of human melanoma cells.
MATERIALS AND METHODS Cells. The M21 human melanoma cell line, originally derived from a metastatic melanoma lesion (5) , was maintained in longterm tissue culture in RPMI-1640 medium-supplemented with 10% fetal calf serum (GIBCO), 2 mM L-glutamine, and 50 ,ug of gentamycin sulfate per ml at 37°C in a humidified 5% COJ/ 95% air atmosphere. Cells used for all experiments exceeded 90% viability by trypan blue exclusion.
Antisera. Monoclonal antibody 9.2.27 was developed in this laboratory from a fusion of the nonsecreting 653 variant of the murine P3-X63-Ag8 myeloma cell line with spleens of BALB/ c mice previously primed with 4 M urea extracts of M21 melanoma cells. The specificity ofthis reagent is reported elsewhere (4) . Spent tissue culture fluid from this hybridoma was the source of antibody for the studies described.
Biosynthetic Labeling and Pulse-Chase Studies. M21 melanoma cells were biosynthetically labeled with radioactive amino acids by incubation in RPMI-1640 Selectamine media (GIBCO) which contained only 25% of the normal amount of unlabeled amino acid to be radiolabeled. These media were supplemented with 10% dialyzed fetal calf serum and gentamycin sulfate (50 pug/ml). M21 cells were intrinsically labeled for the time periods indicated and separated from labeling media by centrifugation. The cell pellets were extracted in RIPA lysis buffer (0.01 M Tris.HCV0.15 M NaCV1% Triton X-100/ 1% deoxycholate/0. 1% NaDodSO4) with 1% Trasylol added (Sigma) as described (6) and used for indirect immunoprecipitation analysis.
In some biosynthetic labeling experiments, monensin (Calbiochem), a monovalent ionophore that can inhibit cell surface expression ofmembrane glycoproteins (7) (8) (9) (10) , was added to the culture medium at the concentrations indicated in the text by dilution ofa 10 mM stock solution in absolute ethanol. The highest ethanol concentration in these labeling experiments was 0.01%, and it had no effect on control glycoprotein biosynthesis.
Pulse-chase studies were initiated by methionine starvation of M21 cells at 2 x 106 cells per ml for 30 min at 37°C in methionine-free RPMI-1640 Selectamine supplemented with 10% dialyzed fetal calf serum.
[3S]Methionine (1 mCi in phosphatebuffered saline; 1 Ci = 3.7 x 10'l becquerels) was then added to initiate a 10-min pulse at 370C, followed by a 1-min centrifugation step and resuspension in chase medium (RPMI-1640 containing 10% fetal calfserum with no radioactive methionine). Aliquots (1-ml) 
RESULTS
Initial studies on the nature of the antigen defined by monoclonal antibody 9.2.27 were performed with biosynthetically labeled M21 melanoma cells that had been exposed to the monovalent ionophore monensin. Recent experiments have shown that monensin affects the cell surface expression and intracellular transport of several glycoproteins and the biosynthesis of proteoglycans (7-10), and we were interested in examining possible biosynthetic precursor components.
When [3H]leucine-labeled cells were extracted in RIPA lysis buffer and analyzed by indirect immunoprecipitation with the 9.2.27 antibody followed by electrophoresis and fluorography (Fig. 1) Fig. 1, lane a) . The complete biosynthesis of this monoclonal antibody-defined antigenic complex occurred between 30 and 60 min into the chase, and the appearance of the HMW C presumably occurred. during and after processing of N-linked oligosaccharides of the 250-kDal component in the Golgi apparatus as judged by the loss of endoglycosidase H sensitivity. Thus, the pulse-chase studies indicate that monoclonal antibody 9.2.27 recognizes a determinant on an N-linked 250-kDal glycoprotein and its precursors early in the chase and that the expression of this determinant does not necessarily require the presence of the HMW C that appears at later steps in the biosynthesis of this complex.
Further experiments involved the use of SO4-labeled M21 human melanoma cells to resolve the nature of the HMW C recognized by monoclonal antibody 9.2.27. Immunoprecipitates from control cell populations revealed a strong band of 'S04-labeled material that was specifically recognized by the monoclonal antibody in the absence of a 250-kDal glycoprotein component (Fig. 3) . Thus, the HMW C apparently is heavily sulfated but the 250-kDal component is not. The migration of this component in the polyacrylamide gel is identical to that observed for the HMW C in immunoprecipitates from 3H-and 'S-labeled M21 melanoma cells (Figs. 1 and 2) . Treatment of this immunoprecipitate in a ,(elimination reaction (19) resulted in a complete breakdown of the HMW C, indicating a high degree of alkali labile O-linkage groups (Fig. 3) . These data eliminate the possibility of the HMW C being related to N-linked fibronectin glycoproteins found in melanoma cells which in our hands migrate considerably faster than the HMW C or the 250-kDal component (i.e., as the 240-kDal component) on NaDodSOJ5% polyacrylamide gel electrophoresis under reducing conditions.
Parallel immunoprecipitates from monensin-treated 35SO4-
labeled cells did not demonstrate the HMW C even with extensive overexposure of fluorographs, indicating a potential biosynthetic block in this component induced by monensin (Fig. 3, lane a) .
The above data suggest strongly that the HMW C is proteo- which was subjected to 3-elimination (19) . Electrophoresis was on NaDodSO4/5% polyacrylamide gels. This fluorograph represents a 96-hr exposure. DF, dye front.
Immunology: Bumol and Reisfeld gree of sulfation, and susceptibility to f-elimination. Additional experiments designed to examine this possibility critically involved the digestion of immunoprecipitates with the proteoglycan-specific enzymes chondroitinase ABC and chondroitinase AC (18) . The results (Fig. 4) A combination of biosynthetic and enzymatic digestion studies of the antigenic determinant recognized by the antimelanoma monoclonal antibody 9.2.27 has allowed us to identify a unique glycoprotein-proteoglycan complex on human melanoma cells. These studies revealed that the 9.2.27 antibody recognizes a 250-kDal, N-linked, sialyated, glycoprotein that can associate with a component expressing the characteristics ofa chondroitin sulfate proteoglycan. The 9.2.27 antibody thus reacts only with melanoma cell lines and freshly explanted surgical melanoma specimens with one exception, a neuroblastoma cell line LA-N-2 (unpublished observations). Taken together, our data suggest not only a restricted expression of this antigenic determinant but also, most interestingly, an association with a: chondroitin sulfate-like proteoglycan common to many tissue types (23, 24) .
Although additional studies are required to understand the precise relationship of the 250-kDal component and the proteoglycan HMW C seen in immunoprecipitates, the increase in the former after chondroitinase digestion (Fig. 4) suggests that this component is contained in the HMW C. This idea is supported by data from preliminary tryptic peptide map analysis by high-performance liquid chromatography (25) , suggesting that essentially all the tryptic peptides of the 250-kDal component are also present in-the chondroitin sulfate proteoglycan molecule together with additional multiple hydrophilic peptides (unpublished data).
Our evidence indicating that monensin can block the appearance of the HMW C in immunoprecipitates obtained with monoclonal antibody 9.2.27 ( Figs. 1 and 3) correlates with findings by Tanzer and colleagues (10) that monensin can affect the biosynthesis ofproteoglycans in chondrocytes. The pulse-chase analyses ofthe endoglycosidase H-treated antigen complex also provide evidence that the appearance of the HMW C is linked kinetically to biosynthetic functions of the Golgi apparatus, the proposed site for the glycosyltransferases involved in proteoglycan biosynthesis (23) . Thus, our data taken together strongly suggest that the 250-kDal glycoprotein may be a'"core" protein onto which chondroitin sulfate proteoglycan side chains are added (23) .
In this regard, current information on the biosynthesis of chondroitin sulfate proteoglycans suggests that a core protein ranging from 200 to 370 kDal serves as the site for the addition of 20 or more chondroitin sulfate oligosaccharides to form the high molecular weight chondroitin sulfate proteoglycan (23, 24, 26) . In one case, the core protein itselfwas a glycoprotein, afact that agrees with our hypothesis suggesting that the 250-kDal component of human melanoma cells also may serve as a core glycoprotein for a chondroitin sulfate proteoglyean (27) . At this point we envision that the monoclonal antibody recognizes both the free pool of core protein and chondroitin sulfate proteoglycan monomer. This hypothesis is strengthened by recent reports describing large pools of free* proteoglycan core protein determined by immunoprecipitation analysis (26) .
Little is known about the biosynthesis of proteoglycans in metastatic human melanoma. However, alterations in the cell surface expression ofproteoglycans have been described in B16 mouse melanoma and several other human tumor systems (28, 29) . In fact, chondroitin sulfate-like proteoglycans have been implicated in these cell surface changes (28, 29) .
The unique specificity of the 9.2.27 monoclonal antibody for a 250-kDal, N-linked, sialyated, glycoprotein associated with a common chondroitin sulfate proteoglycan suggests that the tumor cell may express unique or -modified gene products capable of serving as acceptors or core glycoproteins for common proteoglycan side chains. This type of alteration could account for changes in the proteoglycan makeup of the membranes and extracellular matrix of tumor cells previously described (28, 29) and provides a mechanism for significant structural changes on the tumor cell surface. Further studies on the distribution of Proc. NatL Acad. Sci. USA 79 (1982) 1249 this antigenic determinant in normal and malignant tissues are necessary to verify this hypothesis. However, the approaches outlined here, combining the use of the 9.2.27 monoclonal antibody with biosynthetic and enzymatic studies, have permitted us to identify and obtain structural information of this glyco--protein-proteoglycan complex at the melanoma cell surface without the biochemical isolation of these components. This information will facilitate the design of studies specifically targeted to delineate the functional roles these components may have in the biology of malignant human melanoma.
